The Incretin System: GLP-1 and GIP
The incretin system refers to a group of gut-derived hormones that have been documented as playing central roles in glucose homeostasis and metabolic signaling. The two primary incretin hormones — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — are released from intestinal enteroendocrine cells in response to nutrient ingestion. Published research has documented that these hormones account for a substantial portion of postprandial insulin secretion, a phenomenon termed the incretin effect.
GLP-1 is secreted by L-cells located predominantly in the distal small intestine and colon. Research has documented that GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates central satiety pathways. Endogenous GLP-1 has a very short half-life of approximately two minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
GIP is secreted by K-cells located primarily in the duodenum and proximal jejunum. Published studies have documented that GIP receptor activation stimulates insulin secretion and has been observed to influence lipid metabolism and adipose tissue function. The relationship between GIP signaling and energy balance has been characterized as more complex than initially appreciated, with both agonism and antagonism of the GIP receptor documented as producing metabolic effects in preclinical models.
Understanding the incretin system provides essential context for appreciating the rationale behind multi-receptor agonist research, including work on compounds such as Retatrutide.
GLP-1 Receptor Agonist Research History
The development of GLP-1 receptor agonists represents one of the most significant advances in metabolic peptide research over the past three decades. The first-generation GLP-1 receptor agonists were designed to resist DPP-4 degradation while retaining the ability to activate GLP-1 receptors. Published literature has documented the progression from short-acting compounds requiring multiple daily administrations to long-acting analogs with extended duration of action achieved through albumin binding, Fc fusion, or fatty acid acylation strategies.
Research into GLP-1 receptor agonism has generated a substantial body of published clinical trial data. Studies have documented the effects of GLP-1 receptor activation on glycemic parameters, body weight, and various metabolic markers across multiple patient populations. These findings have been reported in major peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA.
The success of mono-agonist GLP-1 receptor research prompted investigators to examine whether engaging additional receptor targets could produce additive or synergistic metabolic effects. This line of inquiry led to the development of dual and subsequently triple receptor agonist compounds.
From Dual to Triple Agonism
The concept of dual receptor agonism emerged from the observation that GLP-1 and GIP receptor pathways may produce complementary metabolic effects when activated simultaneously. Published research on tirzepatide, a dual GIP/GLP-1 receptor agonist, documented substantial effects on body weight and glycemic parameters in Phase 3 clinical trials, with results published in the New England Journal of Medicine. These findings demonstrated that dual agonism could produce effects that exceeded those documented with mono-agonist approaches.
The progression to triple receptor agonism introduced glucagon receptor activation as a third signaling axis. Glucagon, traditionally characterized as a counter-regulatory hormone that raises blood glucose levels, has also been documented in research as influencing energy expenditure, hepatic lipid metabolism, and amino acid catabolism. Published studies have suggested that the inclusion of glucagon receptor agonism alongside GLP-1 and GIP receptor activation may engage additional metabolic pathways, particularly those related to hepatic fat metabolism and thermogenesis.
The triple agonist concept — simultaneously activating GLP-1, GIP, and glucagon receptors — has been characterized in published literature as an approach designed to leverage complementary and potentially synergistic signaling pathways across multiple metabolic axes.
Retatrutide Phase 2 Trial Findings
Retatrutide is an investigational triple hormone receptor agonist that activates receptors for GIP, GLP-1, and glucagon. The compound is a 39-amino acid peptide linked to a C20 fatty diacid moiety that extends its duration of action.
A Phase 2 clinical trial published in the New England Journal of Medicine by Jastreboff and colleagues in 2023 examined retatrutide in adults with obesity over 48 weeks. The study was a randomized, double-blind, placebo-controlled, dose-finding trial that enrolled participants across multiple treatment groups at varying dose levels. Investigators documented dose-dependent changes in body weight and metabolic parameters across the treatment groups compared to placebo.
A meta-analysis published in 2024, analyzing three randomized controlled trials encompassing 878 patients, reported that retatrutide demonstrated statistically significant effects on body weight, body mass index, waist circumference, fasting plasma glucose, and glycated hemoglobin compared to placebo. These findings have been documented as consistent with the multi-receptor engagement profile of the compound.
Full research summaries and citation details for Retatrutide are available on the Retatrutide research page.
Hepatic Fat Research
Research published in Nature Medicine in 2024 examined retatrutide's effects on hepatic fat content in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD). Investigators documented substantial changes in liver fat measurements at 24 weeks, with reductions in hepatic fat observed across treatment groups.
This area of investigation has been noted in published literature as particularly relevant given the documented role of glucagon receptor signaling in hepatic lipid metabolism. The glucagon receptor component of triple agonism has been proposed to contribute specifically to hepatic effects through mechanisms including increased fatty acid oxidation and reduced lipogenesis, although the relative contributions of each receptor axis remain subjects of ongoing research.
The liver fat findings have been characterized as potentially differentiating triple agonism from dual and mono-agonist approaches, as glucagon receptor activation has been documented in preclinical research as producing hepatic metabolic effects distinct from those associated with incretin receptor activation alone.
Current Phase 3 Research Status
As of early 2026, retatrutide is being evaluated in multiple Phase 3 clinical trials. The TRIUMPH program encompasses several large-scale, randomized, controlled studies examining the compound across various populations and endpoints. Phase 3 TRIUMPH-4 trial results presented in December 2025 documented significant improvements in both weight and pain scores in subjects with knee osteoarthritis over 68 weeks of treatment.
The progression from Phase 2 to Phase 3 trials represents advancement through the standard clinical research pipeline, with Phase 3 studies designed to provide the larger datasets and longer observation periods required for comprehensive evaluation. Published results from the Phase 2 trial and ongoing Phase 3 program continue to contribute to the scientific understanding of triple receptor agonism as a research concept.
Retatrutide is available as part of the Metabolic Stack alongside MOTS-C for laboratory research purposes. Individual vials are also available in the singles catalog.
Research Compliance Disclaimer
All information presented in this article reflects outcomes and observations reported in published research studies and clinical trial data. Retatrutide is sold strictly for in vitro research, laboratory use, and scientific investigation only. It is not intended for human consumption, veterinary use, or any diagnostic or therapeutic application. No information in this article constitutes medical advice or therapeutic guidance.